Research Article
Design of Thymidine Analogues Targeting Thymidilate Kinase of Mycobacterium tuberculosis
Table 2
Complexation energy and its components for the training set of TMPKmt inhibitors: TMD1–TMD15.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
For the chemical structures of the training set of inhibitors see Table 1. b is the molecular mass of the inhibitor. c is the relative enthalpic contribution to the Gibbs free energy change related to the protease-inhibitor complex formation derived by molecular mechanics (MM): PR:TMDxTMDxPR:TMD1TMD1, TMD1—is the reference inhibitor; d is the relative solvation Gibbs free energy contribution to the Gibbs free energy change related to protease-inhibitor complex formation: PR:TMDxTMDxPR:TMD1TMD1; e− is the relative entropic contribution of the inhibitor to the Gibbs free energy related to protease-inhibitor complex formation: ; f comp is the relative Gibbs free energy change related to the enzyme-inhibitor complex formation: . g is the experimental TMPKmt inhibition constant obtained from [15–17]. hRatio of predicted and experimental inhibition constants / was predicted from computed comp using the regression equation for TMPKmt shown in Table 3. |